Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "ARR"

1331 News Found

Roche’s Gazyva hits major milestone in rare kidney disease
Clinical Trials | February 17, 2026

Roche’s Gazyva hits major milestone in rare kidney disease

Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units


Clinigen bags Japan's nod to human milk-based medicine for preterm infants
R&D | February 16, 2026

Clinigen bags Japan's nod to human milk-based medicine for preterm infants

PreemieFort Enteral Solution's approval marks the first time a nutritional product derived from human milk has been recognized as a prescription medicine anywhere in the world


Merck’s KEYTRUDA bags FDA nod for platinum-resistant ovarian cancer
News | February 13, 2026

Merck’s KEYTRUDA bags FDA nod for platinum-resistant ovarian cancer

KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components


Alkem MedTech to acquire 55% stake in Switzerland's Occlutech for €99.4M
Medical Device | February 13, 2026

Alkem MedTech to acquire 55% stake in Switzerland's Occlutech for €99.4M

Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure


Hikal Q3 FY26: Revenue, EBITDA surge amid regulatory recovery
News | February 12, 2026

Hikal Q3 FY26: Revenue, EBITDA surge amid regulatory recovery

The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore


Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery
R&D | February 11, 2026

Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery

The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research


Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke
Clinical Trials | February 07, 2026

Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke

These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke


Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients
Clinical Trials | February 07, 2026

Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients

The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing